非奈利酮联合ACEI/ARB治疗IgA肾病的疗效与安全性
单中心回顾性观察研究纳入52例原发性IgA肾病患者,比较非奈利酮联合ACEI/ARB与单用ACEI/ARB的6个月疗效与安全性。联合组UPCR降幅更大、UPCR更低、白蛋白更高、缓解率更高,eGFR无显著差异,两组均无严重不良事件。
要点
- 非奈利酮联合ACEI/ARB较单用ACEI/ARB显著降低IgA肾病患者6个月UPCR。
- 联合组缓解率73.7%高于单用组39.4%,血清白蛋白更高,eGFR无显著变化。
- 两组均未观察到严重不良事件,联合方案在真实世界中有一定安全性。
核心结论
- 在真实世界环境中,非奈利酮联合ACEI/ARB方案可显著改善IgA肾病患者结局,有效降低蛋白尿并提高血清白蛋白,同时eGFR相对稳定且安全性良好。
研究设计与样本
- 单中心、观察性、回顾性临床研究,纳入52例原发性IgA肾病患者,分为非奈利酮联合ACEI/ARB组(19例)和ACEI/ARB组(33例)。
主要发现
- 两组均未观察到严重不良事件。
临床怎么用
- 对IgA肾病患者,在ACEI/ARB基础上加用非奈利酮可能进一步降低蛋白尿并提高血清白蛋白,且需监测eGFR与不良事件。
局限性
- 本研究为单中心、回顾性、观察性研究,样本量较小(52例),结果需更大规模前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Immunoglobulin A nephropathy (IgAN) is the most common form of glomerulonephritis and a common cause of end-stage kidney disease. This study aimed to evaluate the effectiveness and safety of finerenone in combination with an angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker (ACEI/ARB) regimen in IgAN patients. METHODS: Our study was a single-center, observational, retrospective clinical study. Fifty-two primary IgAN patients were added. Patients were divided into two groups: the finerenone combined with ACEI/ARB group and the ACEI/ARB group. The primary endpoint was treatment response, defined as the percentage change in urinary protein/creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) from baseline to 6 months. The secondary endpoint was the safety of finerenone, with adverse events recorded during treatment. Clinical data were collected from IgAN patients. RESULTS: Of the 52 IgAN patients enrolled, 19 were in the finerenone combined with ACEI/ARB group and 33 in the ACEI/ARB group. At 6 months, the percentage change in UPCR was significantly greater in the finerenone combined with ACEI/ARB group compared with the ACEI/ARB group [-52.10% (interquartile range, IQR -65.71%, -6.12%) vs -21.25% (IQR -39.84%, -6.19%); P = .04]. Furthermore, the UPCR was lower in the finerenone combined with ACEI/ARB group [0.41 g/g (IQR 0.30, 0.72) vs 0.68 g/g (IQR 0.49, 1.10); P = .024]. Serum albumin levels were higher in the finerenone combined with ACEI/ARB group than in the ACEI/ARB group (44.84 ± 2.35 g/L vs 42.96 ± 3.27 g/L; P = .033). No significant changes in eGFR were observed between the groups (P = .091). The response rate was significantly higher in the finerenone combined with ACEI/ARB group compared with the ACEI/ARB group (73.7% vs 39.4%, P = .017). No serious adverse events were observed in either group. CONCLUSIONS: In real-world settings, the finerenone combined with ACEI/ARB regimen significantly improved outcomes in IgAN patients, effectively reducing proteinuria levels and increasing serum albumin levels, while maintaining relatively stable eGFR and exhibiting safety.
引用
- Yu K, Li D, Fan X, et al. Effectiveness and safety of finerenone in IgA nephropathy patients. Nephrol Dial Transplant. 2026. PMID: 41217264. doi:10.1093/ndt/gfaf240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。